Free Trial

Enzon Pharmaceuticals Q4 2023 Earnings Report

Enzon Pharmaceuticals logo
$0.13 0.00 (0.00%)
As of 02/21/2025

Enzon Pharmaceuticals EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Enzon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enzon Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Enzon Pharmaceuticals Earnings Headlines

A deadly mistake in my prediction…
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Enzon Pharmaceuticals Inc ENZN
OKYO Pharma Limited (OK10.F)
See More Enzon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enzon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enzon Pharmaceuticals and other key companies, straight to your email.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals (OTCMKTS:ENZN), together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

View Enzon Pharmaceuticals Profile

More Earnings Resources from MarketBeat